TABLE 1.

Comparison of detection of drug resistance mutations by consensus sequencing and OLA on HIV-1 amplified from plasma or PBMC^c

Mutation type and HIV-1 drug resistance muta- tion analyzed	No. of mutants	Consensus sequencing (%)		OLA (%)
		Plasma RNAa	PBMC DNA	Plasma RNA	PBMC DNA
NRTI
M184V	40	0.0	17.5	27.5	57.5
T215Y	7	0.0	42.9b	28.6	85.7
L74V	5	0.0	0.0b	20.0	40.0
T215F	3	0.0	0.0b	33.3	66.7
K70R	3	0.0	0.0	0.0	33.3
Subtotal	58	0.0	16.9	27.1	59.3
NNRTI
Y181C	9	0.0	55.6	33.3	56.6
K103N	9	0.0	33.3	44.4	33.3
Subtotal	18	0.0	44.4	38.9	44.4
PI
L90M	4	0.0	0.0	25.0	25.0
D30N	4	0.0	0.0b	0.0	25.0
I84V	3	0.0	66.7	33.3	66.7
V82A	2	0.0	0.0b	0.0	50.0
V82S	2	0.0	50b	50.0	100.0
Subtotal	15	0.0	25.0	25.0	50.0
Totalc	91	0.0	23.1	27.5	53.8

^aSamples were selected for this study when consensus sequencing of plasma revealed wild-type or non-drug-resistant virus in an individual whose earlier specimen had encoded one or more drug-resistance mutations.

^bMutations not conferring drug resistance were excluded when calculating the percentage.

^cThe 95% CI values for PBMC DNA from consensus sequencing were 14 to 34; for plasma RNA from OLA were 19 to 39; for PBMC DNA from OLA were 44 to 64.